Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 116 publications
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 30, 2026
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007).
Journal: Journal of the National Cancer Institute
Published: February 06, 2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 25, 2026
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
Journal: JAMA oncology
Published: December 11, 2025
Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer.
Journal: JNCI cancer spectrum
Published: October 20, 2025
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 02, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.
Journal: Journal of the National Cancer Institute
Published: August 22, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Journal: Nature medicine
Published: August 07, 2024
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
Journal: NEJM evidence
Published: July 23, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 27, 2024
Last Updated: 09/26/2026